Lbp Am Sa Raises Stock Holdings in Becton, Dickinson and Company $BDX

Lbp Am Sa boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 3.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 328,138 shares of the medical instruments supplier’s stock after buying an additional 9,851 shares during the period. Becton, Dickinson and Company makes up approximately 0.8% of Lbp Am Sa’s investment portfolio, making the stock its 23rd largest holding. Lbp Am Sa owned 0.11% of Becton, Dickinson and Company worth $61,418,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in BDX. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. RiverGlades Family Offices LLC purchased a new stake in shares of Becton, Dickinson and Company in the second quarter valued at about $344,000. Strs Ohio increased its position in Becton, Dickinson and Company by 31.7% during the third quarter. Strs Ohio now owns 301,430 shares of the medical instruments supplier’s stock worth $56,419,000 after purchasing an additional 72,626 shares during the last quarter. Covea Finance boosted its holdings in Becton, Dickinson and Company by 10.7% in the 3rd quarter. Covea Finance now owns 78,847 shares of the medical instruments supplier’s stock valued at $14,758,000 after purchasing an additional 7,610 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $983,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $201.84 on Monday. The business has a 50-day simple moving average of $197.40 and a 200-day simple moving average of $190.53. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The company has a market cap of $57.51 billion, a PE ratio of 34.62, a P/E/G ratio of 2.23 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. During the same quarter in the previous year, the firm earned $3.81 earnings per share. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were paid a $1.05 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.1%. The ex-dividend date was Monday, December 8th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 2,605 shares of company stock valued at $524,643. 0.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on BDX. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Piper Sandler lowered their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Jefferies Financial Group lifted their price target on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $207.64.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.